Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acrongenomics, Inc.
Acrongenomics on Track to Acquire Molecular Vision
March 2nd, 2008
Acrongenomics, Inc. (OTCBB:AGNM), the Geneva based technology development group have agreed with Molecular Vision and The Imperial Venture Fund a time line for the full acquisition of Molecular Vision. Following the initial acquisition of 10.9% of the shares of Molecular Vision announced earlier this month, it has now been agreed by all parties that the full acquisition of Molecular Vision will be completed before the end of Q1 2008. Acrongenomics is an established company that identifies and then invests in groundbreaking technologies. In May 2006, the Company first identified the combination of microfluidics and light responsive polymers being developed by Molecular...
Source: Pharma Investments, Ventures & Law Weekly (2008-03-02)
|
